Jang-Yen Wu

Prof. Dr. Jang-Yen Wu


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
Jang-Yen WuJang-Yen Wu
Jang-Yen Wu
HPHoward Prentice
Howard Prentice
Taurine demonstrates multiple cellular functions including a central role as a neurotransmitter, as a trophic factor in CNS development, in maintaining the structural integrity of the membrane, in regulating calcium transport and homeostasis, as an osmolyte, as a neuromodulator and as a neuroprotectant. The neurotransmitter properties of taurine are illustrated by its ability to elicit neuronal hyperpolarization, the presence of specific taurine synthesizing enzyme and receptors in the CNS and the presence of a taurine transporter system. Taurine exerts its neuroprotective functions against the glutamate induced excitotoxicity by reducing the glutamate-induced increase of intracellular calcium level, by shifting the ratio of Bcl-2 and Bad ratio in favor of cell survival and by reducing the ER stress. The presence of metabotropic taurine receptors which are negatively coupled to phospholipase C (PLC) signaling pathway through inhibitory G proteins is proposed, and the evidence supporting this notion is also presented.

20 October 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
HPHoward Prentice
Howard Prentice
JMJigar Pravinchandra Modi
Jigar Pravinchandra Modi
Jang-Yen WuJang-Yen Wu
Jang-Yen Wu
In stroke and neurodegenerative disease, neuronal excitotoxicity, caused by increased extracellular glutamate levels, is known to result in calcium overload and mitochondrial dysfunction. Mitochondrial deficits may involve a deficiency in energy supply as well as generation of high levels of oxidants which are key contributors to neuronal cell death through necrotic and apoptotic mechanisms. Excessive glutamate receptor stimulation also results in increased nitric oxide generation which can be detrimental to cells as nitric oxide interacts with superoxide to form the toxic molecule peroxynitrite. High level oxidant production elicits neuronal apoptosis through the actions of proapoptotic Bcl-2 family members resulting in mitochondrial permeability transition pore opening. In addition to apoptotic responses to severe stress, accumulation of misfolded proteins and high levels of oxidants can elicit endoplasmic reticulum (ER) stress pathways which may also contribute to induction of apoptosis. Two categories of therapeutics are discussed that impact major pro-death events that include induction of oxidants, calcium overload, and ER stress. The first category of therapeutic agent includes the amino acid taurine which prevents calcium overload and is also capable of preventing ER stress by inhibiting specific ER stress pathways. The second category involves N-methyl-D-aspartate receptor (NMDA receptor) partial antagonists illustrated by S-Methyl-N, N-diethyldithiocarbamate sulfoxide (DETC-MeSO), and memantine. DETC-MeSO is protective through preventing excitotoxicity and calcium overload and by blocking specific ER stress pathways. Another NMDA receptor partial antagonist is memantine which prevents excessive glutamate excitation but also remarkably allows maintenance of physiological neurotransmission. Targeting of these major sites of neuronal damage using pharmacological agents is discussed in terms of potential therapeutic approaches for neurological disorders.

12 March 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HJHong Jin
Hong Jin
HWHeng Wu
Heng Wu
GOGregory Osterhaus
Gregory Osterhaus
JWJianning Wei
Jianning Wei
KDKathleen Davis
Kathleen Davis
Jang-Yen WuJang-Yen Wu
Jang-Yen Wu
L -Glutamic acid decarboxylase (GAD) exists as both membrane-associated and soluble forms in the mammalian brain. Here, we propose that there is a functional and structural coupling between the synthesis of γ-aminobutyric acid (GABA) by membrane-associated GAD and its packaging into synaptic vesicles (SVs) by vesicular GABA transporter (VGAT). This notion is supported by the following observations. First, newly synthesized [ 3 H]GABA from [ 3 H] l -glutamate by membrane-associated GAD is taken up preferentially over preexisting GABA by using immunoaffinity-purified GABAergic SVs. Second, the activity of SV-associated GAD and VGAT seems to be coupled because inhibition of GAD also decreases VGAT activity. Third, VGAT and SV-associated Ca 2+ /calmodulin-dependent kinase II have been found to form a protein complex with GAD. A model is also proposed to link the neuronal stimulation to enhanced synthesis and packaging of GABA into SVs.

19 August 2012 in Amino Acids
Verified
Journal Article
Closed access
PDF file
JMJanet Menzie
Janet Menzie
CPChunliu Pan
Chunliu Pan
HPHoward Prentice
Howard Prentice
Jang-Yen WuJang-Yen Wu
Jang-Yen Wu

3 June 2013 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JMJanet Menzie
Janet Menzie
HPHoward Prentice
Howard Prentice
Jang-Yen WuJang-Yen Wu
Jang-Yen Wu
Ischemic stroke exhibits a multiplicity of pathophysiological mechanisms. To address the diverse pathophysiological mechanisms observed in ischemic stroke investigators seek to find therapeutic strategies that are multifaceted in their action by either investigating multipotential compounds or by using a combination of compounds. Taurine, an endogenous amino acid, exhibits a plethora of physiological functions. It exhibits antioxidative properties, stabilizes membrane, functions as an osmoregulator, modulates ionic movements, reduces the level of pro-inflammators, regulates intracellular calcium concentration; all of which contributes to its neuroprotective effect. Data are accumulating that show the neuroprotective mechanisms of taurine against stroke pathophysiology. In this review, we describe the neuroprotective mechanisms employed by taurine against ischemic stroke and its use in clinical trial for ischemic stroke.

24 October 2008 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
RLRebecca Leon
Rebecca Leon
HWHeng Wu
Heng Wu
YJYing Jin
Ying Jin
JWJianning Wei
Jianning Wei
CBChandana Buddhala
Chandana Buddhala
Jang-Yen WuJang-Yen Wu
Jang-Yen Wu